{"entity":{"id":"blz-100","kind":"drug","name":"Tozuleristide","aka":["BLZ-100","Tumor Paint"],"tldr":"Tozuleristide is an experimental fluorescent imaging agent from Blaze Bioscience, in phase 3 trials for paediatric central nervous system tumours, breast cancer and glioma and other cancers.","summary":"Tozuleristide (BLZ-100, Tumor Paint) is a fluorescent imaging agent (chlorotoxin-derived peptide conjugated to a near-infrared dye) from Blaze Bioscience. An investigational intraoperative imaging agent whose active component is a chlorotoxin-variant cystine-dense mini-protein conjugated to a near-infrared fluorescent dye; it is taken up and retained by cancer cells so tumour tissue fluoresces under near-infrared imaging during surgery. Its furthest stage is phase 3, for paediatric central nervous system tumours, breast cancer, glioma and skin cancer. ClinicalTrials.gov registers it in 8 studies linked below. Phase 2/3 paediatric CNS trial NCT03579602 completed; FDA Fast Track for paediatric CNS tumours; company now names breast cancer (breast-conserving surgery) as lead indication with an investigator-sponsored trial planned. Whether it works in people has not been established unless a trial below reports it.","status":"phase-3","asOf":"2026-11-03","links":[{"label":"Blaze Bioscience: blazebioscience.com","url":"https://www.blazebioscience.com/technology/"},{"label":"Blaze Bioscience: blazebioscience.com","url":"http://www.blazebioscience.com"},{"label":"Blaze Bioscience: blazebioscience.com","url":"http://www.blazebioscience.com"},{"label":"ClinicalTrials.gov: trials of BLZ-100","url":"https://clinicaltrials.gov/search?intr=BLZ-100"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["brain-tumours","breast-cancer","skin-cancer","head-and-neck","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["blaze-bioscience"],"institutions":[],"pathways":[],"terms":[],"trials":["nct03579602","nct02462629","nct02234297","nct02496065","nct02097875","nct05316688","nct02464332","nct04343274"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"BLZ-100","modality":"Fluorescent imaging agent (chlorotoxin-derived peptide conjugated to a near-infrared dye)","mechanism":"An investigational intraoperative imaging agent whose active component is a chlorotoxin-variant cystine-dense mini-protein conjugated to a near-infrared fluorescent dye; it is taken up and retained by cancer cells so tumour tissue fluoresces under near-infrared imaging during surgery.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/blz-100/","neighbours":{"cancer":[{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/"}],"company":[{"id":"blaze-bioscience","kind":"company","name":"Blaze Bioscience","route":"/companies/blaze-bioscience/"}],"trial":[{"id":"nct05316688","kind":"trial","name":"A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery","route":"/trials/nct05316688/"},{"id":"nct04343274","kind":"trial","name":"Expanded Access for BLZ-100 (Tozuleristide)","route":"/trials/nct04343274/"},{"id":"nct02496065","kind":"trial","name":"Exploratory Study of Safety and ex Vivo Fluorescence of BLZ-100 in Adult Subjects With Solid Tumors Undergoing Surgery","route":"/trials/nct02496065/"},{"id":"nct02097875","kind":"trial","name":"Safety Study of a Fluorescent Marker to Visualize Cancer Cells","route":"/trials/nct02097875/"},{"id":"nct02234297","kind":"trial","name":"Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery","route":"/trials/nct02234297/"},{"id":"nct02464332","kind":"trial","name":"Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery","route":"/trials/nct02464332/"},{"id":"nct02462629","kind":"trial","name":"Study of BLZ-100 in Pediatric Subjects With CNS Tumors","route":"/trials/nct02462629/"},{"id":"nct03579602","kind":"trial","name":"Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery","route":"/trials/nct03579602/"}]}}